The abstract is read at the publisher; the summary is JClub's.
In Japanese males aged 16–26 years, the 9vHPV vaccine prevented vaccine-type anogenital persistent infection with 89·3% efficacy (95% CI 55·4–98·2; p=0·0002) in the initial analysis.
- Why it matters: Efficacy in males was previously inferred from immunobridging, leaving direct male evidence needed to support use for preventing HPV-related anogenital disease.
- What they did: In a randomized, double-blind, placebo-controlled phase 3 trial in Japan, 1059 HPV-uninfected, unvaccinated males received three intramuscular doses of 9vHPV or saline at day 1, month 2, and month 6, with HPV DNA assessed from anogenital swabs and tissue.
- The result: Efficacy was 63·5% (2·7–86·0; p=0·023) for secondary endpoints, seroconversion exceeded 98% for each targeted HPV type, and injection-site adverse events occurred in 70% vs 31% with no deaths or vaccine-related serious adverse events.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.